Patients in single agent dose escalation arm will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.

HER2+ breast cancer patients with brain metastases will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. As long as 2B3-101 is well tolerated, the remaining 95% of the infusion could thereafter be administered over the next 60 min, resulting in a total infusion time of 90 minutes. The infusion of trastuzumab will then follow 30 minutes after the completion of the 2B3-101 infusion.

Patients in the breast, Small Cell Lung Cancer and melanoma dose expansion arms will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.

Patients in the single agent glioma dose expansion arm will receive a single IV dose of 2B3-101 on day 1 of each cycle. In order to minimize the risk of infusion reactions 5% of the total dose of 2B3-101 (in mg) should be infused slowly over the first 30 minutes. If tolerated, the infusion may then be completed over the next hour for a total infusion time of 90 minutes.

Brain Metastases

Lung Cancer

Breast Cancer

Melanoma

Malignant Glioma

2B3-101

Trastuzumab

2B3-101 60 mg/m2 every 4 weeks

2B3-101 50 mg/m2 every 3 weeks

UNC Lineberger Comprehensive Cancer Center

Universitair Ziekenhuis Antwerpen

Jules Bordet Institute

Institut Curie

Institut Gustave Roussy

Antoni van Leeuwenhoek Ziekenhuis

Vrije Universiteit medisch centrum (Vumc)

Leids Universitair Medisch Centrum (LUMC)

Maastricht Universitair Medisch Centrum

Erasmus MC

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

BBB-Therapeutics B.V.

Climacteric Symptoms

Hot Flushes and/or Sweats

TMN-1

Development of Active Safety Surveillance System for Traditional Chinese Medicine

salvia sclarea/rak dojke

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Development of Active Safety Surveillance System for Traditional Chinese Medicine

Najkompletnija baza ljekovitog bilja potpomognuta znanošću